![फेड सितंबर में ब्याज दरों में कटौती करेगा: यूबीएस](https://i-invdn-com.investing.com/news/moved_small-LYNXMPEI5D0I0_L.jpg)
कृपया अन्य खोज का प्रयास करें
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Hyam I. Levitsky | 65 | 2018 | Independent Non-Executive Director |
Christy J. Oliger | 53 | 2021 | Independent Director |
Veleka R. Peeples-Dyer | 51 | 2023 | Independent Director |
Dieter Weinand | 64 | 2018 | Lead Independent Director |
Kapil Dhingra | 65 | 2017 | Independent Director |
Joseph P. Slattery | 59 | 2017 | Independent Director |
Paolo Pucci | 63 | 2020 | Independent Director |
Philip Astley-Sparke | 53 | 2015 | Executive Chairman |
Robert Coffin | 59 | 2015 | Founder, Chief Scientist & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है